Home The Word Brain	My Amedeo FAQ Privacy About
	C49 + CC Journal Club For more information, please refer to our special emails from April 13 and May 19.

Ovarian Neoplasms

Free Subscription Articles published in Oncol Rep Retrieve available abstracts of 16 articles: HTML format

Single Articles

July 2025
1. ZHANG N, Qiu J, Zheng T, Zhang X, et al
   [Corrigendum] Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway.
   Oncol Rep. 2025;54:77.
   PubMed     Abstract available
   
   
   June 2025
2. YANG J, He R, Zhang X, Wang X, et al
   KLC3 activates PI3K/AKT signaling and promotes ovarian cancer cell proliferation and migration through COL3A1.
   Oncol Rep. 2025;53:67.
   PubMed     Abstract available
   
   
   
3. SHEN K, Yuan S, Su N, Tang F, et al
   Monotherapy and combination therapy using antibody?drug conjugates for platinum?resistant ovarian cancer.
   Oncol Rep. 2025;53:68.
   PubMed     Abstract available
   
   
   April 2025
4. CHEN J, He K, Li X, Wang M, et al
   Overexpression of FOS enhances the malignant potential of eutopic endometrial stromal cells in patients with endometriosis?associated ovarian cancer.
   Oncol Rep. 2025;53:45.
   PubMed     Abstract available
   
   
   September 2024
5. DONG YF, Zhang J, Zhou JH, Xiao YL, et al
   Mitochondrial?associated endoplasmic reticulum membrane interference in ovarian cancer (Review).
   Oncol Rep. 2024;52:112.
   PubMed     Abstract available
   
   
   
6. LI X, Guo Y, Xing Z, Gong T, et al
   ABT?737 increases cisplatin sensitivity through the ROS?ASK1?JNK MAPK signaling axis in human ovarian cancer cisplatin?resistant A2780/DDP cells.
   Oncol Rep. 2024;52:122.
   PubMed     Abstract available
   
   
   August 2024
7. LIANG X, Ju J
   [Retracted] Matrine inhibits ovarian cancer cell viability and promotes apoptosis by regulating the ERK/JNK signaling pathway via p38MAPK.
   Oncol Rep. 2024;52:99.
   PubMed     Abstract available
   
   
   March 2024
8. WANG Y, Lin W, Zhuang X, Wang X, et al
   Advances in artificial intelligence for the diagnosis and treatment of ovarian cancer (Review).
   Oncol Rep. 2024;51:46.
   PubMed     Abstract available
   
   
   
9. HOU Y, Zhao X, Nie X
   Enhancing the therapeutic efficacy of NK cells in the treatment of ovarian cancer (Review).
   Oncol Rep. 2024;51:50.
   PubMed     Abstract available
   
   
   July 2023
10. WANG W, Liu S, Lu F, Yang B, et al
    STAT4, a potential predictor of prognosis, promotes CD8 T‑cell infiltration in ovarian serous carcinoma by inducing CCL5 secretion.
    Oncol Rep. 2023;50:140.
    PubMed     Abstract available
    
    
    June 2023
11. YANG X, Li C, Liao X, Liu S, et al
    Paclitaxel induces pyroptosis by inhibiting the volume‑sensitive chloride channel leucine‑rich repeat‑containing 8a in ovarian cancer cells.
    Oncol Rep. 2023;49:115.
    PubMed     Abstract available
    
    
    
12. TAKAHASHI R, Kamizaki K, Yamanaka K, Terai Y, et al
    Expression of Ferredoxin1 in cisplatin‑resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin.
    Oncol Rep. 2023;49:124.
    PubMed     Abstract available
    
    
    May 2023
13. PEI Y, Li K, Lou X, Wu Y, et al
    [Corrigendum] miR‑1299/NOTCH3/TUG1 feedback loop contributes to the malignant proliferation of ovarian cancer.
    Oncol Rep. 2023;49:96.
    PubMed     Abstract available
    
    
    
14. HAN GH, Yun H, Chung JY, Kim JH, et al
    High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer.
    Oncol Rep. 2023;49:102.
    PubMed     Abstract available
    
    
    
15. ZHANG C, Wang R, Li M, Yang Q, et al
    Long non‑coding RNA BLACAT2/miR‑378a‑3p/YY1 feedback loop promotes the proliferation, migration and invasion of uterine corpus endometrial carcinoma.
    Oncol Rep. 2023;49:108.
    PubMed     Abstract available
    
    
    March 2021
16. OTA Y, Koizume S, Nakamura Y, Yoshihara M, et al
    Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix.
    Oncol Rep. 2021;45:1023-1032.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.